METHOD OF TREATING CANCER WITH MAGEA3 IMMUNOTHERAPEUTIC WITH BRAF INHIBITOR AND/OR MEK INHIBITOR

A combination of anti-neoplastic agents that provides increased activity over monotherapy, or in some cases at least an unexpected lack of negative interaction. In particular, the drug combination that includes a MAGE-A3 immunotherapeutic, in combination with a B-Raf inhibitor, particularly N-{3-[5-...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	GERARD, CATHERINE MARIE GHISLAINE, LEHMANN, FREDERIC FRANCOIS EUGENE, LOUAHED, JAMILA, LEBOWITZ, PETER F, LAQUERRE, SYLVIE
Format:	Patent
Sprache:	eng ; fre ; ger
Schlagworte:	AGRICULTURE ANIMAL HUSBANDRY BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES, AS HERBICIDES FISHING FORESTRY HUMAN NECESSITIES HUNTING HYGIENE MEDICAL OR VETERINARY SCIENCE PEST REPELLANTS OR ATTRACTANTS PLANT GROWTH REGULATORS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTSTHEREOF TRAPPING
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	A combination of anti-neoplastic agents that provides increased activity over monotherapy, or in some cases at least an unexpected lack of negative interaction. In particular, the drug combination that includes a MAGE-A3 immunotherapeutic, in combination with a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide, or a pharmaceutically acceptable salt thereof, and/or a MEK inhibitor, particularly N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethy; -2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof is described.